115 related articles for article (PubMed ID: 9369920)
1. [Problems and recommendations for use of G-CSF in lung cancer patients with neutropenia after chemotherapy].
Ogawara M
Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():439-44. PubMed ID: 9369920
[TBL] [Abstract][Full Text] [Related]
2. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
[TBL] [Abstract][Full Text] [Related]
3. [Cytokines in cancer chemotherapy: present state and problems in use of G- and GM-CSF for solid tumors in Japan].
Ogawara M
Gan To Kagaku Ryoho; 1998 Jan; 25(2):164-70. PubMed ID: 9474924
[TBL] [Abstract][Full Text] [Related]
4. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
5. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
7. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia.
Siddiqui T; Burney IA; Kakepoto GN; Khurshid M; Salam A; Smego RA
J Pak Med Assoc; 2002 May; 52(5):206-10. PubMed ID: 12174492
[TBL] [Abstract][Full Text] [Related]
8. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte colony-stimulating factor in neutropenic, pediatric solid tumor patients following chemotherapy.
Ayan I; Kebudi R; Doğan S; Tokuç G; Görgün O
Pediatr Hematol Oncol; 1996; 13(5):417-24. PubMed ID: 10897813
[TBL] [Abstract][Full Text] [Related]
11. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
[TBL] [Abstract][Full Text] [Related]
12. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia.
Haim N; Shulman K; Goldberg H; Tsalic M
Med Oncol; 2005; 22(3):229-32. PubMed ID: 16110133
[TBL] [Abstract][Full Text] [Related]
13. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
Watanabe T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
[TBL] [Abstract][Full Text] [Related]
14. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study.
Ohno R; Miyawaki S; Hatake K; Kuriyama K; Saito K; Kanamaru A; Kobayashi T; Kodera Y; Nishikawa K; Matsuda S; Yamada O; Omoto E; Takeyama H; Tsukuda K; Asou N; Tanimoto M; Shiozaki H; Tomonaga M; Masaoka T; Miura Y; Takaku F; Ohashi Y; Motoyoshi K
J Clin Oncol; 1997 Aug; 15(8):2954-65. PubMed ID: 9256140
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis.
Berghmans T; Paesmans M; Lafitte JJ; Mascaux C; Meert AP; Jacquy C; Burniat A; Steels E; Vallot F; Sculier JP
Support Care Cancer; 2002 Apr; 10(3):181-8. PubMed ID: 11904782
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
Ozkaynak MF; Krailo M; Chen Z; Feusner J
Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the approaches to non-febrile neutropenia developing in children with acute lymphoblastic leukemia.
Paksu MS; Paksu S; Akbalik M; Ozyurek E; Duru F; Albayrak D; Fisgin T
Fundam Clin Pharmacol; 2012 Jun; 26(3):418-23. PubMed ID: 21395681
[TBL] [Abstract][Full Text] [Related]
19. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
Ghalaut PS; Sen R; Dixit G
J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
[TBL] [Abstract][Full Text] [Related]
20. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
Bobey N; Woodman RC
Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
